Coronado Biosciences Granted First U.S. Patent Covering CNDO-109

BURLINGTON, Mass., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for CNDO-109, licensed by Coronado Biosciences from the University College London Business PLC, for its Natural Killer (NK) cell therapy program. The patent, U.S. Patent Application No. 8,257,970, is entitled, "Method for activating natural killer cells by tumor cell preparation in vitro" and has a current expiration date of January 2029.